Verfaillie C, McGlave P
Department of Medicine, University of Minnesota Medical School, Minneapolis 55455.
Blood. 1991 Jan 15;77(2):263-70.
We investigated the in vitro hematopoietic stimulatory activity of leukemia inhibitory factor/human interleukin for DA cells (LIF/HILDA) on bone marrow progenitor populations in 17 normal individuals. In serum-free cultures LIF/HILDA did not induce colony growth. In serum containing media, LIF/HILDA stimulated the growth of colony forming unit (CFU)-MIX and CFU-EO in a dose-dependent fashion and resulted in an increased CFU-MIX and burst forming unit-erythrocytes (BFU-E) colony size. Similar stimulatory effects were seen on a highly purified hematopoietic progenitor population obtained after immunomagnetic depletion of mature myeloid precursors and lymphoid cells. Addition of LIF/HILDA to cultures containing maximally stimulatory concentrations of recombinant human interleukin-3 (rhuIL3), rhuIL3 + rhuIL6, or rhu granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) in serum containing media significantly increased the number of CFU-MIX and eosinophil colonies and increased size and cluster number of CFU-MIX and BFU-E. Depletion of accessory T lymphocytes or monocytes from bone marrow progenitors did not alter the response of hematopoietic precursors to LIF/HILDA. A similar increased colony growth was seen when LIF/HILDA was added to cultures of positively selected CD34/HLA-DR+ or CD34+/HLA-DR- bone marrow hematopoietic progenitor cells stimulated with maximally stimulatory concentrations of rhuIL3 + rhuIL6. LIF/HILDA is a novel cytokine capable of stimulating growth and proliferation of multi-lineage, erythroid, and eosinophil colonies in the presence of serum. LIF/HILDA exerts its activity by direct interaction with highly purified immature bone marrow progenitor cells, has an additive effect when used with other cytokines known to stimulate primitive hematopoietic precursors, and does not require accessory cells.
我们研究了白血病抑制因子/人DA细胞白细胞介素(LIF/HILDA)对17名正常个体骨髓祖细胞群体的体外造血刺激活性。在无血清培养中,LIF/HILDA未诱导集落生长。在含血清培养基中,LIF/HILDA以剂量依赖方式刺激混合集落形成单位(CFU)-MIX和嗜酸性粒细胞集落形成单位(CFU-EO)的生长,并导致CFU-MIX和红细胞爆式集落形成单位(BFU-E)集落大小增加。在用免疫磁珠去除成熟髓系前体细胞和淋巴细胞后获得的高度纯化的造血祖细胞群体上也观察到类似的刺激作用。在含血清培养基中,将LIF/HILDA添加到含有最大刺激浓度的重组人白细胞介素-3(rhuIL3)、rhuIL3 + rhuIL6或重组人粒细胞-巨噬细胞集落刺激因子(rhu GM-CSF)的培养物中,显著增加了CFU-MIX和嗜酸性粒细胞集落的数量,并增加了CFU-MIX和BFU-E的大小和簇数。从骨髓祖细胞中去除辅助性T淋巴细胞或单核细胞不会改变造血前体细胞对LIF/HILDA的反应。当将LIF/HILDA添加到用最大刺激浓度的rhuIL3 + rhuIL6刺激的阳性选择的CD34/HLA-DR+或CD34+/HLA-DR-骨髓造血祖细胞培养物中时,也观察到类似的集落生长增加。LIF/HILDA是一种新型细胞因子,能够在有血清存在的情况下刺激多谱系、红系和嗜酸性粒细胞集落的生长和增殖。LIF/HILDA通过与高度纯化的未成熟骨髓祖细胞直接相互作用发挥其活性,与已知刺激原始造血前体细胞的其他细胞因子一起使用时具有相加作用,并且不需要辅助细胞。